AnaptysBio, Inc. (NASDAQ:ANAB) Director Buys $842,177.28 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Ecor1 Capital, Llc purchased 65,184 shares of the company's stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average cost of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the purchase, the director now owns 7,860,180 shares in the company, valued at $101,553,525.60. This trade represents a 0.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, January 2nd, Ecor1 Capital, Llc purchased 6,646 shares of AnaptysBio stock. The shares were bought at an average price of $12.95 per share, with a total value of $86,065.70.

AnaptysBio Trading Up 0.9 %

Shares of NASDAQ:ANAB traded up $0.12 during mid-day trading on Thursday, reaching $13.36. The company had a trading volume of 465,990 shares, compared to its average volume of 390,740. AnaptysBio, Inc. has a one year low of $12.51 and a one year high of $41.31. The company's 50-day moving average price is $20.10 and its 200-day moving average price is $28.50. The firm has a market cap of $406.53 million, a price-to-earnings ratio of -2.20 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. On average, research analysts anticipate that AnaptysBio, Inc. will post -6.02 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on ANAB shares. HC Wainwright lowered AnaptysBio from a "buy" rating to a "neutral" rating and dropped their target price for the company from $52.00 to $19.00 in a report on Wednesday, December 11th. Guggenheim dropped their price objective on AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, December 12th. BTIG Research lowered shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research note on Monday, December 2nd. Wedbush reiterated an "outperform" rating and issued a $40.00 target price (down previously from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Finally, Truist Financial cut their price target on shares of AnaptysBio from $30.00 to $20.00 and set a "hold" rating on the stock in a report on Wednesday, December 18th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $41.45.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers raised its stake in shares of AnaptysBio by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company's stock valued at $745,000 after purchasing an additional 525 shares during the period. Algert Global LLC increased its position in shares of AnaptysBio by 11.8% during the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company's stock valued at $255,000 after buying an additional 1,078 shares during the period. nVerses Capital LLC increased its position in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after buying an additional 1,400 shares during the period. Values First Advisors Inc. purchased a new stake in shares of AnaptysBio in the third quarter worth about $49,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock valued at $195,000 after acquiring an additional 2,600 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.